Duffy expects to see a second wave of patent expirations, this time involving biosimilars.
“What’s exciting about this space [biosimilars] is the anticipated margins are supposed to be higher than that of their chemically synthesized counterparts,” he says. “Biosimilars are expected to be sold anywhere from a 20 percent to 30 percent discount to the brand name, whereas chemically synthesized generics are sold at an approximately 50 percent to 80 percent discount.”
The GNRX fund has a gross expense ratio of 0.63 percent and a net expense ratio of 0.55 percent, which is capped until February 1, 2017.